Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18900096 | 0.88 | MEN1 (0.44) | MEN1KMT2ARECQL | |
| SCHEMBL24262515 | 0.86 | MEN1 (0.41) | MEN1KMT2ARECQL | |
| SCHEMBL24489203 | 0.85 | MEN1 (0.44) | MEN1KMT2ARECQL | |
| SCHEMBL22923613 | 0.84 | MEN1 (0.40) | MEN1KMT2ARECQL | |
| SCHEMBL18133883 | 0.84 | PAOX (0.42) | — | |
| SCHEMBL23919438 | 0.83 | MEN1 (0.45) | MEN1KMT2ARECQL | |
| SCHEMBL20648082 | 0.82 | MEN1 (0.38) | MEN1KMT2ARECQL | |
| SCHEMBL24376196 | 0.80 | MEN1 (0.45) | MEN1KMT2A | |
| SCHEMBL25896444 | 0.80 | MEN1 (0.48) | MEN1KMT2ARECQL | |
| SCHEMBL24489332 | 0.79 | MEN1 (0.41) | MEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303649-A1 | MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303649-A1 | MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | IL2, IL2RA, ICOS | MEN1 4197/4885KMT2A 1964/4885RECQL 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.